Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
ID: 348995Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348995

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-026.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) focused on schizophrenia and related disorders occurring in mid- to late-life. The initiative aims to advance understanding of the emergence, trajectory, and outcomes of these conditions, with a particular emphasis on identifying intervention targets and prevention strategies. This research is crucial due to the higher morbidity and disability rates among older adults with schizophrenia, highlighting the need for targeted studies to address their unique challenges. Interested applicants can request up to $275,000 in direct costs over two years, with applications due by October 16, 2023, and the funding opportunity remaining open until September 8, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-026.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-026-Full-Announcement.html
    PAR-24-026.html
    The Department of Health and Human Services (HHS) is issuing a Notice of Funding Opportunity (NOFO) for exploratory research grants (R21) focused on schizophrenia and related disorders occurring in mid- to late-life. This funding aims to advance understanding of these conditions' emergence, trajectory, and outcomes, emphasizing the identification of intervention targets and prevention strategies. This initiative invites diverse research teams, particularly those incorporating lived experience insights, to explore biological, psychosocial, and environmental mechanisms affecting older adults with schizophrenia. The total direct costs for projects can reach up to $275,000 over two years, and applications will be reviewed based on scientific merit, innovation, and the investigators’ qualifications. Key dates include an application due date of October 16, 2023, and the funding opportunity expires on September 08, 2026. This research is vital given the higher morbidity and disability among individuals with schizophrenia in this age group, stressing the need for targeted studies to address unique challenges faced by this population.
    Similar Opportunities
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research on schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to explore the mechanisms, trajectories, and outcomes of these disorders, with a focus on identifying targets for prevention and treatment interventions, particularly emphasizing the inclusion of diverse research teams and individuals with lived experience. The funding is available through the R01 grant mechanism, with applications due by September 7, 2026, and interested applicants are encouraged to adhere strictly to the application guidelines and contribute data to the National Institute of Mental Health Data Archive. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Social Disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)" aimed at supporting research on the relationship between social disconnection and suicide risk among older adults. This initiative seeks innovative projects that explore neurobiological, behavioral, and environmental mechanisms influencing social isolation and its impact on suicidal thoughts and behaviors, with an emphasis on promoting health equity and developing interventions to enhance social support. The grant provides a maximum funding amount of $275,000 over a two-year period, with applications due by September 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required). This initiative aims to support innovative clinical trials that investigate novel interventions for mental health conditions, including schizophrenia, depression, and anxiety, with a focus on establishing proof of mechanism and target engagement in the R61 phase and confirming findings on a larger scale in the R33 phase. The total funding commitment for this initiative is $27 million for FY 2022, and eligible applicants include a diverse range of entities such as higher education institutions, nonprofits, and various government organizations, both domestic and foreign. Interested parties should note that the application deadline is October 15, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)," aimed at fostering innovative research methodologies to study brain activity and structural changes over extended periods. This initiative encourages multidisciplinary collaborations to develop novel approaches or adapt existing techniques for measuring brain function across diverse age groups and clinical populations, with a focus on longitudinal data collection at multiple time points. The funding, capped at $275,000 over a two-year period, is intended for high-risk, high-reward exploratory research that enhances understanding of brain development and aging, with applications due by May 16, 2024, and subsequent deadlines. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-161.html.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)" aimed at fostering exploratory and developmental research on brain and nervous system disorders, particularly in low- and middle-income countries (LMICs). This initiative encourages collaborative research projects that span the life cycle and address the increasing burden of neurological conditions, with a focus on building sustainable research capacity and developing culturally appropriate diagnostic and treatment strategies. Eligible applicants include a diverse range of organizations, such as historically black colleges and universities, tribal governments, and foreign entities, with no cost-sharing requirement. The application deadline is December 9, 2024, and interested parties can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-098.html.